ProMIS Neurosciences' Eugene Williams to Present at JLABS' Conference on Innovations in Neurodegenerative Diseases

TORONTO and CAMBRIDGE, MA, May 29, 2019 /PRNewswire/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, is participating in the JLABS @ Toronto conference, "Science 1st: Common Pathways and Mechanisms in Neurodegenerative Diseases" on May 30, 2019. Executive Chairman Eugene Williams will speak at the event, joining speakers from Sunnybrook Research Institute, the University of Toronto, including the Tanz Centre for Research in Neurodegenerative Diseases, Johnson and Johnson Innovations and Conference Sponsor the Ontario Brain Institute.

The one-day program will highlight new findings in genomics, imaging and biomarkers for neurodegenerative diseases. Speakers will describe how these discoveries are redefining these diseases and invigorating the search for treatments. The event will take place at JLABS' Toronto location. Attendees can attend virtually by visiting

The abnormal misfolding of natural proteins in the brain results in toxic oligomers that progressively spread (propagate), killing neurons; the process is a root cause of several neurodegenerative diseases, including Alzheimer's, Parkinson's and ALS. The lack of effective therapies for these diseases is due in part to the traditional approach to developing antibodies, which produced therapy candidates that are unable to selectively target the toxic oligomer with adequate precision. Mr. Williams' presentation will share the results of ProMIS Neurosciences' novel drug discovery and development platform, which has produced several antibody candidates that selectively target toxic oligomers of misfolded proteins while sparing their healthy forms, which are critical for proper brain and spinal cord function. ProMIS has generated high-quality potential antibody candidates for Parkinson's, Alzheimer's and ALS.

"The availability of tools to develop therapies that are highly selective for only the toxic oligomer has been a missing link in therapy development for neurodegenerative diseases," said Eugene Williams, executive chairman of ProMIS Neurosciences. "The right tools coupled with new biomarkers will help us advance only the highest quality drug candidates and in our opinion make this next decade the most exciting for development of effective root cause therapy to address the tremendous unmet need of these diseases."

About Johnson & Johnson Innovation – JLABS
Johnson & Johnson Innovation – JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators across a broad healthcare spectrum including pharmaceutical, medical device, consumer and health tech sectors to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS, we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS also produces campaigns to seek out the best science called QuickFire Challenges. For more information, visit or follow @JLABS.

About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). The Company's proprietary target discovery platform is based on the use of two complementary thermodynamic, computational discovery engines -ProMIS and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.

Visit us at, follow us on Twitter and LinkedIn, and listen to our podcast, Saving Minds, at iTunes or Spotify.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


Cision View original content to download multimedia:

SOURCE ProMIS Neurosciences Inc.